MedDataX Logo

Alleviating Effects Against High Intraocular Pressure by Oral Intake of Cordyceps Cicadae Mycelia

NCT ID: NCT05304299

Last Updated: 2022-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-10

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the effects of lowering intraocular pressure by oral intake of Cordyceps cicadae mycelia, to provide evidence-based data for high intraocular pressure relief.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study purpose This study investigated the effeicacy of oral Cordyceps cicadae mycelia for the relief of high intraocular pressure.

Subjects

1. The total recruitment of subjects is 60 people, aged between 20 to 75 years.
2. Subjects with intraocular pressure more than or equal to 21 mmHg are included, irrespective of whether on us of Taflotan (saflutan).

Methods

1\. Informed consents will be obtained from subjects first. The subjects with pre-test intraocular pressure over or equal 21 mm Hg are advised to orally take two capsules containing a total of 500 mg of Cordyceps cicadae mycelia. After 90 minutes, the subjects are evaluated for intraocular pressure.

The pre-test and and post-intake intraocualr pressure and blood pressure data will be compared by paired t test for significant differences if any.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Supplement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Two groups of subjects are subject to pre-test and post-test intraocular pressure measurements.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cordyceps Cicadae Mycelia only

Only Cordyceps Cicadae Mycelia will be given.

Group Type EXPERIMENTAL

Cordyceps Cicadae Mycelia

Intervention Type DIETARY_SUPPLEMENT

Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.

Cordyceps Cicadae Mycelia with Taflotan (saflutan)

Cordyceps Cicadae Mycelia with Taflotan (saflutan) will be given.

Group Type EXPERIMENTAL

Cordyceps Cicadae Mycelia

Intervention Type DIETARY_SUPPLEMENT

Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cordyceps Cicadae Mycelia

Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age between 20 and 75 years old, regardless of gender.
2. Pre-test confirmation of high intraocular pressure.
3. Subjects should understand the trial and agree to join the project.

Exclusion Criteria

1. Age under 20 or over 75 years.
2. Use intraocular pressure lowering drugs other than Taflotan (saflutan).
3. Using beta-blockers or diuretics.
4. Being pregnant.
5. Disabled individuals with specific diseases or malfunction, for example tumours at terminal stage, blindness.
6. Loss of self-consciousness and behavioral capacity.
7. Patients with major diseases.

Withdrawal criteria All subjects may withdraw at any time without any reason. The act of withdraw does not affect rights for them to seek medical advice or treatments.
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Grape King Bio Ltd.

INDUSTRY

Sponsor Role collaborator

Han-Hsin Chang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Han-Hsin Chang

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Han-Hsin Chang, PhD

Role: PRINCIPAL_INVESTIGATOR

Chung Shan Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Han-Hsin Chang

Taichung, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB-19-024

Identifier Type: -

Identifier Source: org_study_id